Amedisys Inc. (NASDAQ:AMED) was downgraded by equities researchers at Mizuho from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday.

AMED has been the subject of a number of other reports. Wells Fargo & Co. reiterated a “buy” rating on shares of Amedisys in a research report on Sunday, September 11th. Zacks Investment Research lowered Amedisys from a “hold” rating to a “sell” rating in a research report on Tuesday, November 1st. Finally, Jefferies Group restated a “buy” rating and set a $50.00 target price (down from $59.00) on shares of Amedisys in a research report on Tuesday, November 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company. Amedisys currently has a consensus rating of “Hold” and a consensus price target of $50.29.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Shares of Amedisys (NASDAQ:AMED) opened at 41.10 on Wednesday. The firm’s 50-day moving average is $44.72 and its 200-day moving average is $49.04. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of 33.52 and a beta of 1.45. Amedisys has a 1-year low of $31.16 and a 1-year high of $55.16.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Thursday, November 3rd. The company reported $0.36 EPS for the quarter, missing the Zacks’ consensus estimate of $0.44 by $0.08. The firm earned $361.60 million during the quarter, compared to analyst estimates of $361.08 million. Amedisys had a return on equity of 11.94% and a net margin of 2.93%. Amedisys’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.34 earnings per share. On average, analysts predict that Amedisys will post $1.50 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of the stock. State Street Corp raised its position in shares of Amedisys by 6.3% in the first quarter. State Street Corp now owns 686,983 shares of the company’s stock valued at $33,211,000 after buying an additional 40,819 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Amedisys by 53.8% in the first quarter. Goldman Sachs Group Inc. now owns 61,584 shares of the company’s stock valued at $2,977,000 after buying an additional 21,535 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Amedisys by 81.1% in the first quarter. Renaissance Technologies LLC now owns 630,901 shares of the company’s stock valued at $30,498,000 after buying an additional 282,600 shares in the last quarter. Nuveen Asset Management LLC raised its position in shares of Amedisys by 46.2% in the first quarter. Nuveen Asset Management LLC now owns 45,382 shares of the company’s stock valued at $2,193,000 after buying an additional 14,334 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new position in shares of Amedisys during the first quarter valued at about $4,834,000. Institutional investors and hedge funds own 89.64% of the company’s stock.

About Amedisys

Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.

5 Day Chart for NASDAQ:AMED

Receive News & Stock Ratings for Amedisys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc. and related stocks with our FREE daily email newsletter.